News

The Medicines Company announced that the data from 13,941 patients treated in the discontinued CHAMPION Phase III program of cangrelor. CHAMPION program data were analysed after the program’s

Abbott has reported results from the ARBITER 6 – HALTS study showed patients at high cardiovascular risk had significant regression of atherosclerosis after 8 and 14 months of

Glenmark Generics (GGL) has received ANDA approval from the FDA for Ciclopirox Olamine cream, 0.77 % and will commence marketing and distribution of the product in the US

Chadha is president of Balcorp Limited, an international trade and marketing firm, which he founded in 1976 and built into a successful company with about $100 million in

BioInvent International has entered into a licence and discovery agreement with Daiichi Sankyo for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration,

Merck & Co. has released new results from a survey of 1,122 post-menopausal women in Asia found that nearly half (48.5%) were not aware whether or not they

Xanodyne pharmaceuticals has received the FDA approval for its Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilising

Cadence Pharmaceuticals has announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for its priority review of the New Drug Application (NDA)

NicOx has reported that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor (atorvastatin), has met its primary and secondary objectives. The primary top-line results